Best Life Sciences Companies in Emilia Romagna, Italy
The 43 best Life Sciences companies in Emilia Romagna, Italy in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: GreenBone.
Our analysis of 576 Life Sciences companies
$91.7b in tracked funding; 70% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Emilia Romagna
| # | Company | Last round | Disclosed funding | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Apta Regenerative Technologies Smart biomaterials for tissue engineering and 3D cell cultures. | — | — | — | Paola Lagonegro CTO and Founder | — | — | — | — |
| 2 | B&B Dental A range of dental products | — | — | — | Claudio Banzi Founder & CEO | WordPressPleskMySQL+11 | Top 5M | 6 patents Advanced oral implant systems and endodontic instruments for dental procedures. | — |
| 3 | BioMatrix Manufacturer of medical devices and equipment for various hospital departments | — | — | — | Robert Guilleaume CEO | WordPressMySQLPHP+27 | Top 10M | — | — |
| 4 | Callegari Point-of-care diagnostics for clinical chemistry | — | — | — | Renzo Catellani CEO | WebflowMicrosoft ClarityMicrosoft Advertising+12 | Top 10M | 2 patents Analytical kits for measuring antioxidant capacity and free radicals in biological samples. | — |
| 5 | Citieffe Developer of orthopedic fixation systems | — | — | 64 | Fabio Moriggi MD & CEO | WordPressApple iCloud MailGoogle Workspace+30 | Top 10M | — | — |
| 6 | Cizeta Surgical Implantable devices for the treatment of oral-craniomaxillofacial and neurosurgical disorders | — | — | — | Maurizio Marfori Savini CEO & President | PleskPHPNginx+9 | Top 50M | — | — |
| 7 | Dima Italia Respiratory devices for the acute and home care market | — | — | — | Vito Didonn CEO | PHPApache HTTP ServerjQuery+1 | Top 50M | — | — |
| 8 | Holostem Terapie Avanzate Develops cell therapy products based on epithelial stem cells. | — | — | — | Antonio Irione CEO | WordPressMySQLPHP+16 | Top 10M | 22 patents Engineered cell sheet therapies and specialized containers for regenerative medicine applications | — |
Top 12 Life Sciences companies in Emilia Romagna
#1
Series B · Bologna, Emilia Romagna · founded 2013 · 28 employees$8.1Mraised▾
Developer of in-vitro diagnostic products for the detection of cancer. The company has developed ONCOSMART is the first In-Vitro Diagnostic (IVD) system that determines the effectiveness of anticancer drugs for a specific patient, testing live cell response to one or multiple cancer drugs. Additionally, it offers prognostic tests based on the immune profile of hospitalized patients with Coronavirus Disease 19.
- May 2026Series B$8.4M
- Sep 2023Series A$3.8M
- Sep 2022Grant (prize money)$258K
- Dec 2021Seed$2.3M
#2
Series B · Faenza, Emilia Romagna · founded 2014 · 27 employees$26.2Mraised▾
Provider of ortho implants to treat severe fractures and trauma conditions. Their patented technology transforms bamboo into a biomaterial, hydroxyapatite, to provide a bone graft scaffold with high mechanical strength, weight-bearing, and bone regeneration properties needed for large implants. It helps doctors to restore mobility, reduce pain and improve quality of life with a safe, efficacious, and cost-effective solution.
- Oct 2021Grant (prize money)$58K
- Apr 2021Series B$11.9M
- Jun 2017Series A$9.4M
- Sep 2015Series A$3.4M
#3
Series B · Bologna, Emilia Romagna · founded 2013 · 36 employees$10.2Mraised▾
Provider of CO2 injector for diagnostic and interventional peripheral angiography. It offers an automatic injection system for carbon dioxide angiography. Its products include carbon dioxide injector that is used as a contrast medium for pheriperal interventional angiography; and a single use kit, which is composed of French catheters and a custom connection line.
- Feb 2023Series B$7.4M
- Jul 2015Series A$1.6M
- Oct 2013Seed$1.2M
#4
Acquired · Bologna, Emilia Romagna · founded 1999 · 17000 employees$25.5Mraised▾
Developer of lab on a chip technologies for miniaturized cell-biology testing. It offers Ampli1 whole genome amplification (WGA) kit for amplification of DNA content of a single cell and DEPArray technology that helps to trap cells in dielectrophoresis. It also provides DEPArray system, an automated instrument that helps to identify, quantify, and recover individual rare cells and Cell Browser, a software solution that enables image-based selection and recovery of specific cells and cell populations in a sample.
- Feb 2010Series C$16M
- Mar 2007Series A$6.8M
- Jan 2007Unattributed$2.7M
#5
Acquired · Castel Bolognese, Emilia Romagna · founded 1974 · 4 employees$10.6Mraised▾
Comecer designs and manufactures high-technology protective and containment systems for application in nuclear medicine (hot cells, shielded and robotic radiopharmaceuticals dispensing and isolation systems, shielded laminar flow systems), aseptic manufacturing (sterility testing isolator, batch vial filling system, isolated dispensing and weighing systems, mini plants, isolators for fill-finish manufacturing and containment, automated and manual compounding systems, glove integrity testing systems, restricted access barrier systems for crimping machines, modular cell culture isolators, advanced incubator systems for cell therapy applications, and high-performance components) and nuclear power plant components (shielded bunker penetrations, shielded transport containers, shielded waste trolleys, whole body counters, bunker doors, shielded cell for sampling of radioactive waste). The company also offers integrated services through the so-called 1MP (One Manufacturer Practices), where a team of specialists assists customers in building and managing new production centers or PET labs with full GMP compliance, supporting all the operations and validations to obtain the GMP production l
#6
Series A · Carpi, Emilia Romagna · founded 1980 · 70 employees$3.9Mraised▾
Developer of biomedical therapeutic products designed to treat cancer. The company offers products for orthopedics and oncology treatment are effective and have minimal side effects, enabling healthcare providers improve patients' quality of life by developing and producing and safe therapeutic systems for clinical practice.
#7
Public · Bologna, Emilia Romagna · founded 2009 · 16 employees$1.4Mraised▾
Developer of therapeutics for the treatment of cancer in pediatric patients. It has developed and patented a molecule currently undergoing pre-clinical study for the treatment of the three main types of pediatric cancer. Its proprietary biotechnology drug discovery platform to modulate gene transcription claims to have applications in other therapeutic indications including rare genetic disease, neurodegeneration, and other infectious diseases.
- 2014Seed—
- Jun 2013Seed$754.6K
- Feb 2009Seed$608.3K
#8
Deadpooled · Bologna, Emilia Romagna · founded 2007 · 100 employees$816.9Kraised▾
Bio-on is commercializing its proprietary technology for the production of PHAs (polyhydroxyalkanoates), a next generation linear polyester material that the company proposes will replace and improve currently available alternative such as PET, PE, PP, HDPE, LDPE. Their product, MINERV-PHA is a high-performing biopolymer obtained from agricultural co-products or waste that dissolves in normal river or sea water leaving no residue. The company proposes to use this material to develop products such as toys, cosmetics, nanomedical devices for theranostic applications, and for bioremediation applications.
- Nov 2019Grant (prize money)$816.9K
#9
Seed · Modena, Emilia Romagna · founded 2013 · 3 employees$763.5Kraised▾
NeuronGuard has developed a medical device for emergency brain protection to treat patients in case of Acute Brain Damage, directly at the site of the event. Device consists of a refrigerating collar and control unit to provide rapid cooling. Also provides resuscitation and anaesthetics. It is a single device that can be used to resuscitate the patient, provide anaesthesia, as well as induce hypothermia at the point of care. Neuron Guard has developed a portable thermoelectric-operated collar, which refrigerates the neck area. The collar cool the blood flowing to the head and consequently lowering the temperature of the brain and reducing the extent of cerebral damage. The collar is controlled via an external unit that regulates the cooling/heating speed of the device, as well as infusion of anesthetics. Winner of Assodel Award 2015 (Milano, Jul 2015); 1st place Best Practices per l'Innovazione - uP sTart Paolo Traci (Salerno, Jun 2015); 1st place Intel Global Challenge at Berkeley - Internet of Things Hardware (Nov 2014).
- Dec 2015Seed$717K
- Nov 2013Grant (prize money)$337K
- 2013Grant (prize money)$13.3K
- Seed$46.5K
#10
Funding Raised · Parma, Emilia Romagna · founded 2013$434.6Kraised▾
PlumeStars is an Italian biotech working on localized antibiotic drug delivery for infections in Cystic Fibrosis patients. focuses on the development of products that locally deliver very high doses of antibiotics to the lung, especially for infections in cystic fibrosis patients. They have 2 products in the pipeline that are aminoglycoside powders administered by inhalation with a dry powder inhaler. Their technology involves molecular deposition of fatty acids on existing antibiotics to create dry powders for nebulization.
- Oct 2019Grant (prize money)$55.6K
- May 2019Grant (prize money)$56K
- Feb 2017Grant (prize money)$323K
#11
Funding Raised · Imola, Emilia Romagna · founded 2013 · 19 employees$79.4Kraised▾
Cell Dynamics develops research tools for single cell analysis. Its flagship product CellViewer is a single cell analyzer that combines fluorescence time-lapse imaging, automated focal adjustments, environmental culture control and microfluidic media exchange for continuous observations of single cells in life science research. The platform can be used with both liquid and adherent cultures. It also consists of an imaging tool that minimizes the use of fluorescent light to prevent cell damage and enhance better live tracking of cells. Applications include studying of circulating tumor cells and monitoring embryos for IVF.
- Sep 2023Grant (prize money)$79.4K
#12
Funding Raised · Ferrara, Emilia Romagna · founded 2015$345.5Kraised▾
Scent, spun-out from the University of Ferrara, develops screening device for colorectal adenomas, based on the principle of volatile gases emitted by cancer cells. The device SCENT A1, whose prototype is currently available, is being developed to be a low-cost, user-friendly and portable device; it aims to improve the preventive screening of colorectal adenomas carried out on the stool collected from the patient, analyzing the composition of the gases emitted by the cancer cells.
- Jun 2019Grant (prize money)—
- Nov 2015Grant (prize money)$345.5K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Italy
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,095 Italy-affiliated papers.
- University of Milan77
- University of Naples Federico II54
- University of Padua51
- University of Bologna49
- University of Bari Aldo Moro48
- Gene3→16
- Transcription (linguistics)1→7
- DNA damage3→8
- Mitochondrion1→5
- Phosphorylation1→4
- Antimicrobial1→15
- Quality (philosophy)1→15
- Antioxidant1→13
- Crop2→14
- Fermentation1→13
- Agriculture2→15
- Antibiotic resistance1→14
- Food safety2→12
- Sustainability1→8
- Livestock1→6
Where biotechnology is researched across Italy
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.